BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6420144)

  • 1. Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man.
    Küpfer A; Lawson J; Branch RA
    Epilepsia; 1984 Feb; 25(1):1-7. PubMed ID: 6420144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mephenytoin hydroxylation deficiency: kinetics after repeated doses.
    Küpfer A; Desmond P; Patwardhan R; Schenker S; Branch RA
    Clin Pharmacol Ther; 1984 Jan; 35(1):33-9. PubMed ID: 6690169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
    Küpfer A; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
    Küpfer A; Brilis GM; Watson JT; Harris TM
    Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
    J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography.
    Küpfer A; James R; Carr K; Branch R
    J Chromatogr; 1982 Oct; 232(1):93-100. PubMed ID: 7142342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
    Jacqz E; Hall SD; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
    Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
    J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography.
    Meier UT; Kronbach T; Meyer UA
    Anal Biochem; 1985 Dec; 151(2):286-91. PubMed ID: 4096368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
    Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
    J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
    Schellens JH; van der Wart JH; Breimer DD
    Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of R-enantiomeric normephenytoin during chronic administration in epileptic patients.
    Bourgeois BF; Küpfer A; Wad N; Egli M
    Epilepsia; 1986; 27(4):412-8. PubMed ID: 3720699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the epoxide-diol pathway in the biotransformation of mephenytoin.
    Gerber N; Thompson RM; Smith RG; Lynn RK
    Epilepsia; 1979 Jun; 20(3):287-94. PubMed ID: 446437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
    Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
    Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mephenytoin hydroxylation in the Cuna Amerindians of Panama.
    Inaba T; Jorge LF; Arias TD
    Br J Clin Pharmacol; 1988 Jan; 25(1):75-9. PubMed ID: 3370193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man.
    Desiderio C; Fanali S; Küpfer A; Thormann W
    Electrophoresis; 1994 Jan; 15(1):87-93. PubMed ID: 8143685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.